Intelgenx(IGXT) MC $54M /2 NDA Submission withn 3 months Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Intelgenx(IGXT) MC $54M /2 NDA Submission withn 3 months

IGXT 0.167

0.0%

May 27 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: BioHero	11/3/2017 10:31:38 AM
	of 4

Great time to load up nowafter they resubmit the NDA for Rizaport early this week .GL RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines..November 1, 2017 finance.yahoo.com Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive . Intelgenx (IGXT) Markt-Cap $48 Million Cash 8.1 Million Price: $0.73 FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million) NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million) Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug) Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired MEGA Pipeline s2.q4cdn.com Presentation s2.q4cdn.com investorintel.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext